Eli Lilly (LLY) will partner with Nvidia (NVDA) to launch an artificial intelligence co-innovation lab based in the San Francisco Bay area with the goal of using AI to accelerate drug discovery.
Lilly scientists will work together with Nvidia AI model builders and engineers “to generate large-scale data and build powerful AI models that can accelerate medicine development.” Nvidia’s BioNeMo platform will be central to the lab’s work.
The two companies will invest up to $1B in talent and infrastructure over five years.
At the start, the lab will “focus on creating a continuous learning system that tightly connects Lilly’s agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists,” according to a news release. “This scientist-in-the-loop framework aims to enable experiments, data generation and AI model development to continuously inform and improve one another.”
Lilly and Nvidia are not strangers to each other. In October 2025, the drugmaker said it would build a supercomputer in collaboration with Nvidia to power an “AI factory.”
